Standout Papers

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer 2019 2026 2021 2023 575
  1. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer (2019)
    Aditya Bardia, Ingrid A. Mayer et al. New England Journal of Medicine

Immediate Impact

11 by Nobel laureates 12 from Science/Nature 72 standout
Sub-graph 1 of 20

Citing Papers

Natural killer cell therapies
2024 StandoutNature
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2023 Standout
7 intermediate papers

Works of William A. Wegener being referenced

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
2020
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
2015
and 6 more

Author Peers

Author Last Decade Papers Cites
William A. Wegener 1816 2141 1107 120 4.6k
Devron H. Char 1254 1790 635 231 6.2k
Yvette L. Kasamon 2218 2077 947 99 5.7k
Russell J. Schilder 1528 3294 2552 148 7.8k
Wei Wei 1099 1761 783 239 5.0k
H. Graeff 1260 2211 431 208 7.4k
Stanley E. Order 1528 1236 664 147 4.7k
Robin Joyce 830 1507 1378 92 3.9k
A. Z. S. Rohatiner 1047 3076 4099 117 6.7k
John D. Earle 1115 1596 1200 126 6.8k
Arturo Molina 2278 2486 1720 161 7.7k

All Works

Loading papers...

Rankless by CCL
2026